Aerska develops next-generation RNA medicines specifically engineered for systemic administration and targeted delivery across the blood-brain barrier. The company leverages precision medicine approaches to silence disease-causing genes within the central nervous system. This focus aims to transform the treatment landscape for debilitating brain diseases by offering potent and durable therapeutic options.

Axonis Therapeutics is developing first-in-class oral KCC2 potentiator drugs, specifically targeting the KCC2 protein to restore functional inhibition in the brain. This approach aims to address neurological disorders such as epilepsy and pain by enhancing inhibitory signaling within the central nervous system.

Beacon utilizes an EEG neurobiomarker platform powered by machine learning to enhance clinical trial efficiency and optimize treatment strategies for neurological and psychiatric disorders. By providing quantitative assessments of brain activity, the platform enables precise dose selection and patient stratification, improving the likelihood of successful treatment outcomes.

The startup has developed a patient-reported outcome assessment tool that integrates with electronic health record systems to enhance the management of chronic pain therapies. This platform enables healthcare professionals to capture real-world evidence and optimize patient engagement through improved documentation and real-time data analysis.

CatenaBio’s CysTyr platform enables site‑specific conjugation of two or more drug payloads to a single antibody using a stable cystine‑tyrosine (C‑Y) bond. The resulting multi‑payload ADCs support flexible drug‑to‑antibody ratios and accommodate large or complex molecules, aiming to overcome resistance and improve therapeutic index in solid‑tumor indications. The technology integrates with existing antibody manufacturing processes for pharmaceutical and biotech developers.

ClexBio develops VivoSet™ technology to create fully vascularized therapeutic tissues that restore lost cell and organ function by providing a supportive microenvironment for embedded therapeutic cells. This approach addresses the critical shortage of viable organ transplants and offers new treatment options for chronic diseases like Type 1 diabetes and advanced liver disease.

The startup develops clinical data software that utilizes artificial intelligence and natural language processing to extract relevant clinical data points and create unified patient graphs from fragmented medical documents. This technology enables healthcare professionals to efficiently identify and match eligible patients to clinical trials, enhancing recruitment processes and improving trial outcomes.

EpiWatch is a smartwatch application that detects tonic-clonic seizures and alerts caregivers, enabling timely assistance to reduce the risk of injury or sudden unexpected death in epilepsy (SUDEP). The platform also facilitates medication reminders and seizure logging, empowering individuals with epilepsy to manage their condition more effectively.

Mensura Health develops a point‑of‑care diagnostic system that quantifies anti‑seizure medication levels from a small blood sample during a patient visit. The portable instrument delivers quantitative results within minutes and integrates with electronic health records, allowing neurologists and epileptologists to adjust dosing instantly. This rapid, on‑site therapeutic drug monitoring aims to improve seizure control and reduce the need for separate laboratory testing.

The startup develops a bioelectronic medical device utilizing micro-electrodes to provide personalized treatment for polycystic ovary syndrome (PCOS). This technology enables medical practitioners to enhance women's metabolic and reproductive health through a wearable solution that offers safe and effective therapeutic options.

Pragma Bio utilizes an AI-enabled, biology-first platform to discover novel small molecules targeting the gut-immune axis for therapeutic development. The platform, PIKASO, mines clinically-relevant Biosynthetic Gene Clusters (BGCs) using multi-omics data to identify de-risked starting points for new medicines. This approach leverages naturally evolved molecules to uncover disease-modifying pathways and accelerate small molecule drug discovery.

Prudentia Sciences provides a unified platform that centralizes internal and external drug data, applies expert‑crafted scientific diligence frameworks, and uses AI to generate evidence‑based assessments for licensing, M&A, and partnership decisions. The system enables corporate development, business development, and investment teams to screen, prioritize, and continuously re‑evaluate assets while mapping competitive landscapes and modeling valuation scenarios, all within a single, auditable workflow.

Ryght AI provides a generative AI platform utilizing "AI Site Twins," which are digital replicas of global clinical research sites. This technology enables sponsors and CROs to rapidly identify, select, and activate optimal sites based on protocol analysis. The platform continuously optimizes site performance throughout the trial lifecycle to accelerate patient enrollment.

Scaffold Therapeutics develops RNA-targeted cancer therapies using machine learning to analyze and regulate RNA modifications that affect stability, transcription, and degradation. Their platform accelerates drug discovery across oncology and neurodegenerative diseases by providing insights into pathway biology and aligning experimental research with clinical objectives.

Soovu develops a patented wearable device that utilizes pulsed heat technology for drug-free relief of chronic and musculoskeletal pain, as well as menstrual discomfort. This clinically proven system delivers targeted thermal neuromodulation, providing measurable pain reduction and improved mobility, with users experiencing relief in as little as four hours.

Tuva Health develops open-source software that normalizes and unifies unstructured healthcare data from various sources, including claims and medical records, into a longitudinal data model. This platform enables healthcare organizations to enhance data quality, streamline analytics, and significantly reduce data platform costs by up to 90%.

Zafrens utilizes nanofabrication to analyze and manipulate diverse cell populations at single-cell resolution, generating paired longitudinal imaging and sequencing data. This technology enables high-throughput drug discovery across various modalities, enhancing our understanding of cellular behavior and facilitating scientific discoveries at an unprecedented scale.

Zenith Health provides a personal research assistant, Penny, to deliver clear, credible, and evidence-based information regarding pregnancy care. This platform empowers expectant parents to make confident decisions by replacing anecdotal information with researched responses. Furthermore, the company facilitates the Pregnancy Evidence Project, transforming user experiences into data to improve future maternal health research and outcomes.

Zeto offers a wireless, dry electrode EEG headset designed for hospital use, eliminating the need for gel application and extensive preparation. This technology enables rapid and efficient brain activity monitoring, improving patient comfort and streamlining clinical workflows.